Clinical Outcome Assessments for Spasticity: Review, Critique, and Recommendations.

Autor: Gal O; Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University, Prague, Czech Republic.; Department of Neurology, General University Hospital in Prague, Prague, Czech Republic., Baude M; Service de Rééducation Neurolocomotrice, Hôpitaux Universitaires Henri-Mondor, Assistance publique-Hôpitaux de Paris, Créteil, France.; BIOTN Laboratory, EA 7377 BIOTN, Université Paris-Est Créteil, Créteil, France., Deltombe T; Department of Physical Medicine & Rehabilitation, CHU UCL Namur Site Godinne, Yvoir, Belgium., Esquenazi A; Jefferson Moss-Magee Rehabilitation, Philadelphia, Pennsylvania, USA., Gracies JM; BIOTN Laboratory, EA 7377 BIOTN, Université Paris-Est Créteil, Créteil, France.; Service de Neurorééducation, Université de Corse, Centre Hospitalier de Bastia, Bastia, France., Hoskovcova M; Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University, Prague, Czech Republic.; Department of Neurology, General University Hospital in Prague, Prague, Czech Republic., Rodriguez-Blazquez C; National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.; CIBERNED, Institute of Health Carlos III, Madrid, Spain., Rosales R; Faculty of Medicine and Surgery-Research Center for Health Sciences and Dept. Of Neuroscience, University of Santo Tomas (and Hospital), Manila, Philippines., Satkunam L; Division of Physical Medicine & Rehabilitation, Glenrose Rehabilitation Hospital, Edmonton, Alberta, Canada.; Department of Medicine, University of Alberta, Edmonton, Alberta, Canada., Wissel J; Neurology and Psychosomatic at Wittenbergplatz, Berlin, Germany.; University of Potsdam, Potsdam, Germany., Mestre T; Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.; University of Ottawa Brain and Mind Institute, Ottawa, Ontario, Canada., Sánchez-Ferro Á; CIBERNED, Institute of Health Carlos III, Madrid, Spain.; Movement Disorders Unit, Neurology Department, Hospital Universitario Instituto de Investigación Sanitaria (imas12) 12 de Octubre, Madrid, Spain., Skorvanek M; Department of Neurology, P. J. Šafárik University, Košice, Slovakia.; Department of Neurology, University Hospital of L. Pasteur, Košice, Slovakia., Tosin MHS; Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA., Jech R; Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University, Prague, Czech Republic.; Department of Neurology, General University Hospital in Prague, Prague, Czech Republic.
Jazyk: angličtina
Zdroj: Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2024 Dec 04. Date of Electronic Publication: 2024 Dec 04.
DOI: 10.1002/mds.30062
Abstrakt: Background: Spasticity is a common feature in patients with disruptions in corticospinal pathways. However, the term is used ambiguously. Here, spasticity is defined as enhanced velocity-dependent stretch reflexes and placed within the context of deforming spastic paresis encompassing other forms of muscle overactivity.
Objective: This scoping review aims at evaluating the clinimetric quality of clinical outcome assessments (COAs) for spasticity across different pathologies and to make recommendations for their use.
Methods: A literature search was conducted to identify COAs used to assess spasticity. An international expert panel evaluated the measurement properties in the included COAs. Recommendations were based on the MDS-COA program methodology based on three criteria: if the COA was (1) applied to patients with spastic paresis, (2) used by others beyond the developers, and (3) determined to be reliable, valid, and sensitive to change in patients with spasticity.
Results: We identified 72 COAs of which 17 clinician-reported outcomes (ClinROs) and 6 patient-reported outcomes (PROs) were reviewed. The Tardieu Scale was the only ClinRO recommended for assessing spasticity. One ClinRO-Composite Spasticity Index-and two PROs-Spasticity 0-10 Numeric Rating Scale and 88-Item Multiple Sclerosis Spasticity Scale-were recommended with caveats. The Ashworth-derived COAs were excluded after evaluation due to their focus on muscle tone rather than spasticity, as defined in this review.
Conclusions: The Tardieu Scale is recommended for assessing spasticity, and two PROs are recommended with caveats. Consistent terminology about the various types of muscle overactivity is necessary to facilitate their assessment and treatment. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
(© 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.)
Databáze: MEDLINE
Externí odkaz: